Journal
NUTRIENTS
Volume 15, Issue 8, Pages -Publisher
MDPI
DOI: 10.3390/nu15081850
Keywords
gut microbiota; bile acids; cardiovascular disease; atherosclerosis
Categories
Ask authors/readers for more resources
Despite advancements in prevention and treatment, cardiovascular disease (CVD) remains the leading cause of death worldwide. Recent studies have highlighted the potential role of non-traditional factors, such as the gut microbiota and its metabolites, in CVD. Specifically, disturbances in the gut microbiota and altered bile acid metabolism have been associated with CVD development. Bile acids, apart from their role in lipid absorption and metabolism, have been found to act as signaling molecules and modulate cardiometabolic pathways, making them potential therapeutic targets in CVD.
Despite advances in preventive measures and treatment options, cardiovascular disease (CVD) remains the number one cause of death globally. Recent research has challenged the traditional risk factor profile and highlights the potential contribution of non-traditional factors in CVD, such as the gut microbiota and its metabolites. Disturbances in the gut microbiota have been repeatedly associated with CVD, including atherosclerosis and hypertension. Mechanistic studies support a causal role of microbiota-derived metabolites in disease development, such as short-chain fatty acids, trimethylamine-N-oxide, and bile acids, with the latter being elaborately discussed in this review. Bile acids represent a class of cholesterol derivatives that is essential for intestinal absorption of lipids and fat-soluble vitamins, plays an important role in cholesterol turnover and, as more recently discovered, acts as a group of signaling molecules that exerts hormonal functions throughout the body. Studies have shown mediating roles of bile acids in the control of lipid metabolism, immunity, and heart function. Consequently, a picture has emerged of bile acids acting as integrators and modulators of cardiometabolic pathways, highlighting their potential as therapeutic targets in CVD. In this review, we provide an overview of alterations in the gut microbiota and bile acid metabolism found in CVD patients, describe the molecular mechanisms through which bile acids may modulate CVD risk, and discuss potential bile-acid-based treatment strategies in relation to CVD.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available